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DownThe purpose of this study was to evaluate the anticancer potency and mechanism of a novel difluorodiar-
ylidenyl piperidone (H-4073) and its N-hydroxypyrroline modification (HO-3867) in human ovarian cancer.
Studies were done using established human ovarian cancer cell lines (A2870, A2780cDDP, OV-4, SKOV3,
PA-1, and OVCAR3) as well as in a murine xenograft tumor (A2780) model. Both compounds were compa-
rably and significantly cytotoxic to A2780 cells. However, HO-3867 showed a preferential toxicity toward
ovarian cancer cells while sparing healthy cells. HO-3867 induced G2-M cell cycle arrest in A2780 cells
by modulating cell cycle regulatory molecules p53, p21, p27, cyclin-dependent kinase 2, and cyclin, and
promoted apoptosis by caspase-8 and caspase-3 activation. It also caused an increase in the expression of
functional Fas/CD95 and decreases in signal transducers and activators of transcription 3 (STAT3; Tyr705)
and JAK1 phosphorylation. There was a significant reduction in STAT3 downstream target protein levels in-
cluding Bcl-xL, Bcl-2, survivin, and vascular endothelial growth factor, suggesting that HO-3867 exposure
disrupted the JAK/STAT3 signaling pathway. In addition, HO-3867 significantly inhibited the growth of
the ovarian xenografted tumors in a dosage-dependent manner without any apparent toxicity. Western blot
analysis of the xenograft tumor tissues showed that HO-3867 inhibited pSTAT3 (Tyr705 and Ser727) and JAK1
and increased apoptotic markers cleaved caspase-3 and poly ADP ribose polymerase. HO-3867 exhibited
significant cytotoxicity toward ovarian cancer cells by inhibition of the JAK/STAT3 signaling pathway.
The study suggested that HO-3867 may be useful as a safe and effective anticancer agent for ovarian cancer
therapy. Mol Cancer Ther; 9(5); 1169–79. ©2010 AACR.Introduction
Ovarian cancer is the second most commonly diag-
nosed gynecologic malignancy among women in the
United States (1, 2). The current standard of care includes
primary surgical cytoreduction followed by administra-
tion of cisplatin or cisplatin in combination with taxanes
(3). Long-term administration of cisplatin has been
shown to result in the development of chemotherapeutic
drug resistance in the cancer cell population (4, 5). An in-
crease in the cisplatin resistance of ovarian tumors re-
quires the administration of larger doses of the drug
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on January 14, 2015mct.aacrjournals.org loaded from multiorgan toxicities (6). Many chemotherapeutic drugs
induce the production of reactive oxygen species, which
are toxic to both cancerous and healthy cells. To reduce
the side effects of chemotherapy and improve the quality
of life, the majority of cancer patients use antioxidants in
combination with conventional therapies. Unfortunately,
adding antioxidants adjunctively may compromise the
efficacy of these conventional therapeutic strategies (7).
Signal transducer and activator of transcription 3
(STAT3) has been implicated in the pathogenesis of a va-
riety of human malignancies including head and neck
cancer, myeloma, prostate cancer, breast cancer, colon
cancer, and ovarian cancer (8–11). Activation of STAT3
can be accomplished by the Janus kinases (JAK; includ-
ing TYK2), activated epidermal growth factor receptor,
and Src kinase (12). STAT3 is constitutively activated in
many tumor types and this activation promotes acceler-
ation of cell proliferation, upregulation of survival fac-
tors, and activation of antiapoptotic proteins. This
imparts cellular resistance to chemotherapy by inhibiting
apoptosis in epithelial malignancies, including ovarian
cancer (13, 14). Because of its important role in oncogen-
esis, STAT3 has attracted much attention as a potential
pharmacologic target for cancer treatment (11, 15, 16).1169
. © 2010 American Association for Cancer Research. 
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Published OnlineFirst May 4, 2010; DOI: 10.1158/1535-7163.MCT-09-1207 Curcumin, a β-diketone constituent of turmeric de-
rived from the rhizome of the plant Curcuma longa, has
been shown to inhibit the many cellular signaling path-
ways, including the JAK-STAT pathway, and to down-
regulate the expression of many tumor-promoting
downstream proteins and signaling cascades (16, 17).
Curcumin has been shown to have antiproliferative and
antiangiogenic activities in several tumors, including
ovarian cancer (18, 19). However, the clinical use of cur-
cumin has been limited due to its low anticancer activity
and poor absorption. Recently, a novel class of curcumin
analogues, diarylidenyl piperidones (DAP), has been
developed by incorporating a piperidone link to the
β-diketone structure and fluorosubstitutions on the phenyl
groups (20). The DAP compounds, in general, were moreMol Cancer Ther; 9(5) May 2010
on January 14, 2015mct.aacrjournals.org Downloaded from effective than curcumin in inhibiting the proliferation of a
variety of cancer cell lines (21). EF24, one of the DAP
compounds with ortho-fluorinated phenyl groups, exhib-
ited potent anticancer efficacy in vitro when tested using
breast cancer (21), colon cancer (22), and ovarian epithe-
lial cancer (23) cell lines. Subsequently, we observed that
H-4073 (Fig. 1), a para-fluorinated variant, was more po-
tent than EF24 in inducing cytotoxicity to ovarian cancer
cells (24, 25).
A nonspecific cytotoxic compound may have side ef-
fects caused by damage to normal cells. For example,
many chemotherapeutic agents act by producing free ra-
dicals, which may increase oxidative stress in normal cells
(26, 27). To minimize this toxicity, there is a need to use
detoxicants, such as antioxidants, which can differentiateFigure 1. Inhibition of cell viability and proliferation by HO-3867. Structures of curcumin, H-4073, and HO-3867 are shown. H-4073 is a 3,5-diarylidenyl
piperidone containing a para-fluorosubstitution on the phenyl groups. HO-3867 contains an N-hydroxy-pyrroline moiety covalently linked to the
NH2-terminus of piperidone. In aerated solutions and cells, the N-hydroxy-pyrroline undergoes conversion to and exists in equilibrium with the nitroxide
(>NO) form (shown in the circle). A, dose-dependent effect of curcumin, H-4073, and HO-3867 on the viability of A2780 cells. Cells were incubated
with curcumin, H-4073, or HO-3867 for 24 hours followed by measurement of cell viability (by MTT assay). Columns, mean (n = 5); bars, SEM.
B, dose-dependent effect of H-4073 and HO-3867 on the colony-forming ability of A2780 cells. Columns, mean (n = 5); bars, SEM. C, effect of H-4073
and HO-3867 (10 μmol/L; 24 h) on the viability of different ovarian cancer cell lines: A2780R (cisplatin-resistant variation of A2780), SKOV3, OV3, and
OVCAR3. Columns, mean (n = 5); bars, SEM. D, dose- and incubation time–dependent effect of HO-3867 (10 μmol/L) on the viability of hOSE, a human
ovary surface epithelial cell line used as a healthy control. Columns, mean (n = 5); bars, SEM. *, P < 0.05 versus the effect of H-4073 at equivalent doses.Molecular Cancer Therapeutics
. © 2010 American Association for Cancer Research. 
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Published OnlineFirst May 4, 2010; DOI: 10.1158/1535-7163.MCT-09-1207 between healthy and cancerous cells and selectively pro-
tect the healthy cells by scavenging free radicals (28, 29). It
has been shown that nitroxides, a class of small-molecu-
lar-weight heterocyclic molecules containing “>NO,” and
hydroxylamines, the one electron–reduced form of nitrox-
ides characterized by “>NOH,” preferentially scavenge
oxygen radicals in cells that have normal oxygenation
or redox status (30, 31). Hydroxylamines are called “pro-
nitroxides,” as the hydroxylamine form of the molecules
exists in equilibrium with the nitroxide form in well-
oxygenated tissues (30, 31). Most tumors are hypoxic in
nature and their cellular environment is more reducing
(for example, thiol rich) when compared with healthy
cells (32, 33). This differential aspect between normal
and cancerous cells has led us to the design of HO-3867
(Fig. 1), which would have both anticancer and anti-
oxidant properties (25). Hence, the specific goals of the
present study were (a) to determine the anticancer effica-
cy of HO-3867 toward cancerous and a noncancerous
(control) cell lines, (b) to derive mechanistic insights
into the action of HO-3867, and (c) determine whether
HO-3867 would significantly inhibit tumor growth in an
in vivo model of ovarian cancer. The studies were con-
ducted using human ovarian cancer cell lines and amurine
xenograft model of ovarian cancer. The results showed a
preferential toxicity of HO-3867 toward ovarian cancer
cells and suppression of tumor growth through inhibition
of the JAK/STAT3 pathway both in vitro and in vivo.
Materials and Methods
Chemicals
Curcumin, superoxide dismutase, 6-carboxy-2′,7′-
dichlorodihydrofluorescein diacetate, diacetoxy-methyl
ester, MTT, and antibodies against actin were ob-
tained from Sigma. 5-Diethoxyphosphoryl-5-methyl-1-
pyrroline-N-oxide was from Radical Vision. Cell-culture
medium (RPMI 1640), fetal bovine serum, antibiotics, so-
dium pyruvate, trypsin, and PBS were purchased from
Life Technologies. Polyvinylidene fluoride membrane
and molecular weight markers were obtained from Bio-
Rad. Antibodies against poly-adenosine diphosphate ri-
bose polymerase (PARP), cleaved caspase-3, caspase-7,
caspase-8, STAT3, phospho-STAT3 (Tyr705), JAK1, Bcl-
xL, and phospho-JAK1 (Tyr1022/1023) were purchased
from Cell Signaling Technology. Antibodies specific for
cyclin A, cyclin D1, cyclin-dependent kinase (Cdk)2,
p53, p21, p27, Fas/CD95, FasL, Bcl-2, and ubiquitin were
purchased from Santa Cruz Biotechnology. Enhanced
chemiluminescence reagents were obtained from Amer-
sham Pharmacia Biotech (GE Healthcare). All other re-
agents, of analytical grade or higher, were purchased
from Sigma-Aldrich unless otherwise noted.
Synthesis of H-4073 and HO-3867
Melting points were determined with a Boetius micro-
melting point apparatus and are uncorrected. Elemental
analyses (C, H, N, S) were done on a Fisons EA 1110www.aacrjournals.org
on January 14, 2015mct.aacrjournals.org Downloaded from CHNS elemental analyzer. Mass spectra were recorded
on Thermoquest Automass Multi and VG TRIO-2 instru-
ments the EI mode. 1H NMR spectra were recorded with
a Varian UNITYINOVA 400 WB spectrometer. Chemical
shifts are referenced to Me4Si. Measurements were run at
298K probe temperature in a CDCl3 solution. Flash col-
umn chromatography was done on a Merck Kieselgel
60 (0.040–0.063 mm). Qualitative thin-layer chromatogra-
phy was carried out on commercially prepared plates
(20 × 20 × 0.02 cm) coated with Merck Kieselgel GF254.
All chemicals were purchased from Aldrich. Compound
HO-350 was prepared as described earlier (34).
(3E,5E)-3,5-Bis(4-fluorobenzylidene)piperidin-4-one
(H-4073). A solution of 4-fluorobenzaldehyde (2.48 g,
20.0 mmol) and 4-piperidone hydrate hydrochloride
(1.53 g, 10.0 mmol) was allowed to stay in glacial acetic
acid (saturated with HCl gas previously) for 2 days. The
precipitated yellow solid was filtered, washed with Et2O
(30 mL), and the yellow hydrochloride salt 2.50 g (72%;
melting point, 212–214°C) was air dried and used in the
next step without further purification. For analytic char-
acterization, 300 mg of the salt were dissolved in water
(10 mL) and basified by addition of 250 mg K2CO3 and ex-
tractedwith CHCl3 (3 × 10mL). The combined extracts were
dried (MgSO4), filtered, and evaporated to obtain a yellow
solid compound [Rf: 0.43 (CHCl3/Et2O, 2:1). MS (EI,
70 eV): m/z (%): 311 (M+, 73) 282 (43), 148 (36), 133(100).
Anal Calcd. for: C19H15F2NO: C 73.30; H 4.86; N 4.50.
Found: C 73.19; H 4.83; N 4.32. 1H NMR (399.9 MHz,
DMSO-d6): δ 4.38 (s, 4 H), 7.26 (t, 4 H), 7.48 (m, 4H), 7.81
(s, 2H)].
1-[(1-Oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-
yl)methyl]-(3E,5E)-3,5-Bis(4-fluorobenzylidene)piperidin-
4-one (HO-3867). A mixture of H-4073 HCl salt (1.73 g,
5.0 mmol) and K2CO3 (1.38 g, 10.0 mmol) in acetonitrile
(20 mL) was stirred at room temperature for 30 minutes.
Then, allylic bromide and HO-350 (1.28 g, 5.5 mmol)
were added dissolved in acetonitrile (5 mL) and the mix-
ture was stirred and refluxed till the consumption of the
starting materials (∼3 h). After cooling, the inorganic
salts were filtered off on sintered glass filter, washed with
CHCl3 (10 mL), the filtrate was evaporated, and the res-
idue was partitioned between CHCl3 (20 mL) and water
(10 mL). The organic phase was separated; the aqueous
phase was washed with CHCl3 (20 mL); and the com-
bined organic phase was dried (MgSO4), filtered, and
evaporated. The residue was purified by flash column
chromatography (Hexane/EtOAc) to obtain the deep yel-
low solid title compound [1.36 g (59%), Rf: 0.57 (Hexane/
EtOAc, 2:1), mp 142-144°C. MS (EI, 70 eV): m/z (%): 463
(M+, 12) 433 (20), 324 (40), 310 (43), 133(100). Electron
spin resonance: aN = 14.9 G. Anal Calcd. for :
C28H29F2N2O2: C 72.55; H 6.31; N 6,04. Found: C 72.54;
H 6.23; N 6.04].
To achieve theN-hydroxy compoundHCl salt, HO-3867
(1.0 g) was dissolved in ethanol (20 mL, saturated with
HCl gas previously) and refluxed for 30 minutes. Then,
the solvent was evaporated off and the procedure wasMol Cancer Ther; 9(5) May 2010 1171
. © 2010 American Association for Cancer Research. 
Selvendiran et al.
1172
Published OnlineFirst May 4, 2010; DOI: 10.1158/1535-7163.MCT-09-1207 repeated till the disappearance of the electron paramag-
netic resonance triplet line to give the HCl salt.
A detailed report on the synthesis and structure-
activity relationship of a number of DAP derivatives will
be published separately (35). Stock solutions of the com-
pounds were freshly prepared in DMSO.
Cell lines and cultures
The A2780 human epithelial ovarian cancer cell line
was used for most parts of the study. Other ovarian can-
cer cell lines used (SKOV3, OVCAR3, A2780R, and OV4),
as were normal human ovarian surface epithelial (hOSE;
ScienCell Ovarian Cell System) cells, were grown in
RPMI 1640 and DMEM supplemented with 10% fetal bo-
vine serum, 2% sodium pyruvate, 1% penicillin, and 1%
streptomycin. Cells were grown in a 75-mm flask to 70%
confluence at 37°C in an atmosphere of 5% CO2 and 95%
air. Cells were routinely trypsinized (0.05% trypsin/
EDTA) and counted using an automated counter
(NucleoCounter, New Brunswick Scientific).
Cell viability by MTT assay
Cell viability was determined by a colorimetric assay
using MTT. In the mitochondria of living cells, yellow
MTTundergoes a reductive conversion to formazan, pro-
ducing a purple color. Cells, grown to ∼80% confluence
in 75-mm flasks, were trypsinized, counted, seeded in 96-
well plates with an average population of 7,000 cells per
well, incubated overnight, and then treatedwith curcumin,
H-4073, or HO-3867 for 24 hours. All experiments were
done using eight replicates and repeated at least thrice.
Cell proliferation by clonogenic assay
Cell survival was assessed by clonogenic assay. Cells at
∼80% confluence were trypsinized, rinsed, seeded onto
60-mm dishes (5 × 104 cells per dish), grown for 24 hours
at 37°C, and treated afterward with H-4073 or HO-3867
for 24 hours. Nontreated cells served as controls. After
treatment, the cells were washed twice with PBS, trypsi-
nized, counted, and plated in 60-mm dishes in triplicate
and incubated for an additional 7 days. The colonies
were then stained with crystal violet (in ethyl alcohol)
and counted using an automated colony counter (ColCount,
Oxford Optronix). Each experiment was repeated at
least five times.
Cell-cycle analysis
Cells were treated with HO-3867 (10 μmol/L) for
24 hours, trypsinized, washed in PBS, and fixed in an
ice-cold 75% ethanol/PBS solution. The DNA was
labeled with propidium iodide. Cells were sorted by flow
cytometry and cell cycle profiles were determined using
ModFit LT software (Becton Dickinson).
Immunoblot analysis
Cells in RPMI 1640 were treated with DMSO (control)
or HO-3867 (10 μmol/L) for 24 hours. Equal volumes of
DMSO (0.1% v/v) were present in each treatment. Fol-Mol Cancer Ther; 9(5) May 2010
on January 14, 2015mct.aacrjournals.org Downloaded from lowing treatment, the cell lysates were prepared in non-
denaturing lysis buffer containing 10 mmol/L Tris-HCl
(pH 7.4), 150 mmol/L NaCl, 1% Triton X-100, 1 mmol/L
EDTA, 1 mmol/L EGTA, 0.3 mmol/L phenylmethyl-
sulfonyl fluoride, 0.2 mmol/L sodium orthovanadate,
0.5% NP40, 1 μg/mL aprotinin, and 1 μg/mL leupetin.
The lysates were centrifuged at 10,000 × g for 20 minutes
at 4°C and the supernatant was separated. The protein
concentration in the lysates was determined using a Pierce
detergent–compatible protein assay kit. For Western blot-
ting, 25 to 50 μg of protein lysate per sample were dena-
tured in 2× SDS-PAGE sample buffer and subjected to
SDS-PAGE on a 10% tris-glycine gel. The separated pro-
teins were transferred to a polyvinylidene fluoride mem-
brane andwere blockedwith 5%nonfatmilkpowder (w/v)
in TBST (10 mmol/L Tris, 10 mmol/L NaCl, 0.1% Tween
20) for 1 hour at room temperature or overnight at 4°C. The
membranes were then incubated with the primary anti-
bodies. The bound antibodies were detected with horse-
radish peroxidase–labeled sheep anti-mouse IgG or
horseradish peroxidase–labeled donkey anti-rabbit IgG
using an enhanced chemiluminescence detection system
(ECLAdvanced kit). Protein expressionswere determined
using the Image Gauge v. 3.45 software.
Ovarian cancer tumor xenografts in mice
Cultured A2780 cancer cells (2 × 106 cells in 60 μL of
PBS) were s.c. injected into the back of 6-week-old
BALB/c nude mice from the National Cancer Institute.
Five to 7 days later, when the tumors reached 3 to 5 mm
in diameter, the mice were divided (n = 9/group) in a
manner to equalize the mean tumor diameter among
the groups. The control group was given a normal diet
(no treatment), whereas the experimental groups were
treated using the DAP compounds mixed with the animal
feed (Harlan Teklad) at three different levels (25, 50, and
100 ppm). The doses were chosen based on an initial dose-
response study optimized to produce an observable effect
on tumor growth. The size of the tumor was measured
twice per week using a digital Vernier caliper. The tumor
volume was determined from the orthogonal dimensions
(d1, d2, d3) using the formula (d1 × d2 × d3) × π/6. Thirty
five days after the beginning of HO-3867 treatment, the
mice were sacrificed and the tumors were resected. The
tumor tissueswere then subjected to immunoblot analysis.
Data analysis
The statistical significance of the results was evaluated
using ANOVA and a Student's t test. A P value of <0.05
was considered significant.
Results
HO-3867 is cytotoxic to A2780 and other ovarian
cancer cell lines
The cytotoxic effects of H-4073 and HO-3867 were
evaluated and compared with that of curcumin in
A2780 and other established human ovarian cancer cellMolecular Cancer Therapeutics
. © 2010 American Association for Cancer Research. 
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Published OnlineFirst May 4, 2010; DOI: 10.1158/1535-7163.MCT-09-1207 lines. Fig. 1A compares the effect of curcumin, H-4073,
and HO-3867 on the viability of A2780 cells. Although
all three compounds showed a dose-dependent cytotoxi-
city, H-4073 and HO-3867 exhibited significantly higher
toxicity when compared with curcumin. The results fur-
ther indicated that the cytotoxic effects of HO-3867 and
H-4073 on A2780 cells were comparable, suggesting that
the introduction of the N-hydroxypyrroline moiety in
HO-3867 did not compromise the cytotoxic effect of
HO-3867 against A2780 cells. We next did clonogenic as-
says to study the effectiveness of H-4073 and HO-3867 on
the proliferation of A2780 cells. Both compounds showed
a dose-dependent reduction in the number of colonies
(Fig. 1B), suggesting that the compounds are equally po-
tent in inhibiting cell proliferation. We further tested the
cytotoxicity of H-4073 and HO-3867 in a number of other
well-established human ovarian cancer cell lines includ-
ing a cisplatin-resistant derivative of A2780 (A2780R),
PA-1, SKOV3, OV4, and OVCAR3. The results (Fig. 1C)
showed that both H-4073 and HO-3867 were equally and
significantly toxic to the tested cell lines. We then tested
the effect of HO-3867 exposure on hOSE cells, which are
noncancerous control cell lines derived from human
ovarian surface epithelium. As shown in Fig. 1D, no sig-
nificant cytotoxicity to hOSE cells was observed for up to
10 μmol/L concentration of HO-3867. However, treat-
ment with 20 μmol/L H-4073 or HO-3867 showed sig-
nificant cytotoxicity to hOSE cells. Taken together, the
cellular viability studies showed that both H-4073 and
HO-3867 were comparably and significantly effectivewww.aacrjournals.org
on January 14, 2015mct.aacrjournals.org Downloaded from in inducing cytotoxicity in A2780 and other ovarian
cancer cell lines; however, HO-3867 was significantly
less toxic to noncancerous hOSE cells when compared
with H-4073.
HO-3867 induces G2-M cell cycle arrest in
A2780 cells
We next examined whether the growth inhibition of
A2780 cells by HO-3867 was caused by cell cycle arrest.
Cells were treated with HO-3867 for 6, 12, or 24 hours;
fixed; and cell cycle populations were determined by
flow cytometry. The results showed that the percentages
of the cell population in the G2-M and sub-G1 phases
were significantly higher in the treatment group when
compared with the nontreated control group (Fig. 2A
and B). We then determined the effect of HO-3867 on
the cell cycle regulatory molecules p53, p21, p27, cdk2,
and cyclin A (Fig. 2C) by Western blotting. The levels
of p53 and p21 were significantly upregulated, whereas
cdk2 and cyclin-A levels were significantly decreased
after treatment (Fig. 2D). These results indicated that
HO-3867 caused G2-M cell cycle arrest, at least in part,
by modulating cell cycle regulatory proteins.
HO-3867 induces apoptosis in A2780 cells
The arrest of cell cycle progression in cancer cells is
usually associated with the concomitant activation of
proapoptotic pathways. To determine whether HO-
3867–induced cell cycle arrest led to apoptosis, the expres-
sion of activated caspaseswere probed byWestern blotting.Figure 2. Modulation of cell cycle
progression and cell cycle
regulatory proteins by HO-3867.
A2780 cells were treated with
HO-3867 for 6, 12, or 24 hours.
A, representative flow cytometry
profiles of control (0 μmol/L) and
HO-3867 (20 μmol/L) treatment
groups at different time periods.
B, quantitative cell cycle (DNA
content) distribution (% of total) in
the control and treatment groups.
Columns, mean (n = 5); bars, SD;
*, P < 0.01 versus control.
C, immunoblot images of cell cycle
regulatory proteins. D, quantitative
results of p53, p21, cdk2, and
cyclin A bands. Columns, mean
(n = 5); bars, SD; *, P < 0.01 versus
control (0 μmol/L); a.u., arbitrary
units.Mol Cancer Ther; 9(5) May 2010 1173
. © 2010 American Association for Cancer Research. 
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Published OnlineFirst May 4, 2010; DOI: 10.1158/1535-7163.MCT-09-1207 The blots showed the activation of caspase-8, caspase-7,
cleaved caspase-3, and PARP in A2780 cells treated with
HO-3867 for 24 hours (Fig. 3A). The quantitative results
of the immunoblots (Fig. 3B) showed a significant increase
in the level of these caspases in cells treated with HO-3867
when compared with nontreated cells. We further deter-
mined the levels of caspase-8–associated death receptors
such as Fas/CD95 and Fas-L. The data from the Fas/
CD95 expression showed a clear increase in HO-3867–
treated cells when compared with nontreated group.
However, no significant change was observed in Fas-L
(data not shown).Mol Cancer Ther; 9(5) May 2010
on January 14, 2015mct.aacrjournals.org Downloaded from HO-3867 inhibits the JAK/STAT3 pathway
The constitutive activation of STAT3 in ovarian cancer
has been shown to regulate the expression of genes im-
plicated in tumor-cell proliferation and survival (36, 37).
To determine whether the HO-3867–induced growth
inhibition in A2780 cell was mediated by STAT3, we
examined the level of phosphorylated STAT3 (pSTAT3)
by Western blotting (Fig. 4A). The pSTAT3 (Tyr705
and Ser727) levels were significantly decreased after
treatment with 10 or 20 μmol/L HO-3867 for 24 hours.
Excessive JAK activity in tumor cells is one of the most
common mechanisms for constitutive activation of
STAT3. To examine whether HO-3867 exposure resulted
in a decrease in STAT3 activation through JAK kinase in-
hibition, we measured the phosphorylated level of JAK1
after 24 hours of exposure to 10 or 20 μmol/L HO-3867
(Fig. 4A). In addition, we cross-checked the expression of
these proteins using immunoprecipitation and confirmed
the decreased expression of pSTAT3 and pJAK1 with no
change in the total expression levels of these proteins.
The data showed a substantial decrease in phospho-
JAK1 (Tyr1022/1023) when compared with unexposed
controls, suggesting that HO-3867 blocked the JAK/
STAT3 pathway. Before proceeding to in vivo experi-
ments, we confirmed the potent apoptosis-inducing ef-
fect of HO-3867 in four additional ovarian cancer cell
lines, A2780R, SKOV3, OV4, and OVCAR3. Following
HO-3867 treatment, all four cell lines clearly showed cas-
pase-3 and PARP cleavage, accompanied by a decrease in
the expression levels of pSTAT3 and JAK1 (Fig. 4B). The
results suggested that induction of apoptosis and inhibi-
tion of JAK/STAT3 signaling could be caused by HO-
3867 in human ovarian cancer cell lines.
HO-3867 downregulates the STAT3 target proteins
To investigate the downstream consequences of STAT3
inhibition, Western blotting was done to determine the
protein levels of Bcl-xL, Bcl-2, survivin, vascular endo-
thelial growth factor (VEGF), and cyclin D1 following
24-hour exposure to HO-3867 at 10 and 20 μmol/L con-
centrations. There was a clear reduction in Bcl-xL, Bcl-2,
survivin, and VEGF levels, whereas no significant change
in cyclin D1 level was observed (Fig. 4C). Because these
proteins are involved in anti-apoptotic (survivin, Bcl-2,
and Bcl-xL) and angiogenic (VEGF) protein expressions,
the downregulation of these proteins suggested profound
antitumor potential of HO-3867 in ovarian cancer cells.
The results clearly showed the involvement of the STAT3
pathway in the growth inhibition of the A2780 ovarian
cancer cells by HO-3867.
HO-3867 inhibits the growth of xenograft
tumor in mice
Based on our in vitro results, which showed significant
cytotoxicity of HO-3867 to human ovarian cancer cell
lines, we next evaluated the efficacy of HO-3867 in a hu-
man ovarian tumor xenograft grown in the back of mice.
The mice were treated with HO-3867 and the tumor sizeFigure 3. Induction of apoptosis by HO-3867. A2780 cells were treated
with HO-3867 for 24 hours and subjected to Western blot analysis for
apoptotic marker proteins. A, representative immunoblot images of
FAS/CD95, cleaved caspases (cle. casp; 8, 7, and 3), and PARP.
B, quantitative results of immunoblot. Columns, mean (n = 5) expressed
as arbitrary units; bars, SD; *, P < 0.01 versus control (0 μmol/L).Molecular Cancer Therapeutics
. © 2010 American Association for Cancer Research. 
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Published OnlineFirst May 4, 2010; DOI: 10.1158/1535-7163.MCT-09-1207 was measured twice weekly for 5 weeks as reported
(10, 15). A significant reduction in the tumor volume was
observed in a dose-dependent manner; particularly, the
doses of 50 and 100 ppm were more effective when
compared with vehicle-treated controls (Fig. 5). We also
measured the body weight and diet consumption of
tumor-bearing animals. HO-3867–treated animals did not
show any gross signs of toxicity and/or possible adverse
side effects as measured by two profiles: body weight
(Fig. 5C) and diet consumption (Fig. 5D). These resultswww.aacrjournals.org
on January 14, 2015mct.aacrjournals.org Downloaded from suggest the in vivo antitumor efficacy of HO-3867 against
ovarian tumor without any apparent signs of toxicity.
HO-3867 inhibits pSTAT3 and downregulates the
STAT3-targeting proteins in vivo
We further analyzed the excised tumor tissue to deter-
mine whether HO-3867 inhibited the STAT3/JAK protein
expression levels, as observed in the in vitro studies. In
concert with the decreased expressions in both pSTAT3
Tyr705 and Ser727 levels, without affecting total STAT3,Figure 4. Inhibition of JAK/STAT3-signaling
and downstream proteins by HO-3867.
Cells were treated with HO-3867 for 24 hours
and subjected to Western blot analysis.
A, representative immunoblot images of
phosphorylated and total STAT3 and JAK1 in
A2780 cells and immunoprecipitation results
of pSTAT3 (Tyr705/Ser727) and pJAK1
(Tyr1022/1023) using bands captured by STAT3
or JAK1 and blotted with pSTAT3 or pJAK1.
B, representative Western blots obtained from
four other ovarian cancer cell lines (A2780R,
SKOV3, OV4, and OVCAR3) treated with
10 μmol/L HO-3867 for 24 hours. Note the
decreased levels of pJAK1 and pSTAT3, and
corresponding increased levels of cleaved
caspase-3 and cleaved PARP in the treated
cells compared with nontreated cells.
Densitometric analysis of Western blots are
shown for pJAK1, pSTAT3, cleaved caspase-3,
and cleaved PARP. Columns, mean (n = 5)
expressed as arbitrary units; bars, SD.
C, immunoblot images of Bcl-xL, Bcl-2,
survivin, cyclin D1, and VEGF proteins in cells.
Quantitative results of Bcl-xL, Bcl-2, survivin,
and VEGF bands are shown. Columns, mean
(n = 5) expressed as a percent of control
(*, P < 0.01); bars, SD.Mol Cancer Ther; 9(5) May 2010 1175
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Published OnlineFirst May 4, 2010; DOI: 10.1158/1535-7163.MCT-09-1207 we observed a clear downregulation of total JAK levels in
tumor tissues. However, we did not observe any signifi-
cant change in pJAK levels in tumor tissues (Fig. 6A). As
for the target gene products of STAT3, we observed a clear
decrease of cyclin D1, VEGF, Bcl-2, and Survivin levels in
the HO-3867–treated tumors (Fig. 6B). Interestingly, we
noticed a significant induction of cleaved caspase-3 and
PARP, which is a knownmarker of apoptosis and a down-
stream target of activated caspase-3 (Fig. 6C and D;
ref. 38), suggesting that HO-3867 induced apoptosis in vivo.
Discussion
The results of the present study established that the di-
fluorodiarylidenyl piperidone, HO-3867, exhibits potent
anticancer efficacy toward human ovarian cancer cells
and xenograft tumors. HO-3867, which also incorporates
an antioxidant function, exhibits substantially lower tox-
icity toward noncancerous cells. The mechanistic studies
revealed that HO-3867 targets multiple pathways, in-
cluding altering the proteins involved in G2-M cell cycle
arrest, increased expression of Fas/CD95, downregula-
tion of antiapoptotic signals, and inhibition of the JAK/
STAT3 pathway in both in vitro and in vivo.
Cell cycle control plays a critical role in the regulation
of tumor cell proliferation. Many cytotoxic agents arrest
cell cycle at the G1, S, or G2-M phase. In the present study,
HO-3867 induced G2-M cell cycle arrest in A2780 cells as
evidenced by a significant increase in the p53, p21, andMol Cancer Ther; 9(5) May 2010
on January 14, 2015mct.aacrjournals.org Downloaded from p27 protein levels. We also observed a significant reduc-
tion in Cdk2 and cyclin A levels. Previous studies have
shown that the G2-M-phase progression is regulated by
a number of Cdk/cyclins as well as Cdk inhibitors such
as p21 and p27 (23). Hence, our results suggest that the
HO-3867–induced G2-M cell cycle arrest is mediated by
the induction of p53 and p21 and downregulation of
cyclin A and Cdk2.
Many curcumin derivatives induce apoptosis in cancer
cells, but the mechanisms by which they do so differ (22,
23). The death receptor–associated mechanism has been
recently receiving much attention for the anticancer activ-
ity of curcumin derivatives (39, 40). We observed that the
death receptor gene Fas/CD95 was activated in A2780
cells by HO-3867. We further observed that the expres-
sion level of TNF-R1, the receptor of tumor necrosis
factor-α, was unchanged in the HO-3867–treated A2780
cells (data not shown). It has been reported that curcumin
promoted tumor necrosis factor-α–induced apoptosis in a
variety of cancer cells, but without a significant increase
in the TNF-R1 expression level. Curcumin and curcumin
analogues have also been shown to upregulate death re-
ceptor 5 and FasL expression, thereby inducing apoptosis
in human cancer cells (23, 41). Thus, our results suggest a
critical involvement of upregulated death receptor super-
family–mediated signals in the stimulation of A2780
apoptosis following HO-3867 exposure.
STAT3 has been shown to suppress the transcription of
Fas/CD95 (42). This suggests the HO-3867–mediatedMole
. © 2010 American AssociatioFigure 5. Effect of HO-3867 on
murine xenograft tumors. A, a
dose-dependent decrease in the
volume of the xenograft tumors
growth is observed following
HO-3867 treatment. B, final
volume of HO-3867–treated
tumors at the 5th week. C, change
in body weight and D,
consumption of feed containing
HO-3867 over time. Points, mean
from nine mice in each group; bars,
SEM. *, P < 0.05 versus nontreated
control group.cular Cancer Therapeutics
n for Cancer Research. 
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Published OnlineFirst May 4, 2010; DOI: 10.1158/1535-7163.MCT-09-1207 downregulation of STAT3 expression, in both in vitro and
in vivo, as a putative mechanism for increased Fas/CD95
expression. This is obvious from the substantial decrease
in the level of Tyr705-pSTAT3, a major active form of ac-
tivated STAT3. It is noteworthy that the expression level
of Ser727-pSTAT3 was also clearly decreased in vivo. Be-
cause the Ser727 phosphorylation is also known to regu-
late the transcriptional activity of STAT3 (20, 21), this
attenuated phosphorylation is suggested to participate
in the downregulation of the transcriptional activity of
STAT3 in the xenograft tumor treated with HO-3867.
We also observed that HO-3867 caused a substantial in-
hibition of phospho-JAK1 (Tyr-1022/1023), suggesting
that HO-3867 can inhibit the constitutive activation of
STAT3, which may be caused, at least in part, by the in-
hibition of pJAK1. However, HO-3867 may also inhibit
STAT3 activation through JAK2, Src, Erb2, and epidermal
growth factor receptor, which are implicated in STAT3 ac-
tivation as well. Additional studies are needed to explore
these pathways.
Downstream proteins of STAT3 have been shown to
regulate apoptosis and regulation in cancer cells. For ex-
ample, Bcl-xL, Bcl-2, and survivin have been shown to
suppress apoptosis, whereas c-myc and cyclin D1 have
been shown to mediate proliferation (43, 44). Because of
the fact that STAT3-downregulating genes are all critical-
ly involved in the development of cancer aggressiveness,
targeting STAT3 is considered a potential anticancer strat-
egy. Furthermore, inhibition of STAT3 expression in vivo
has provided deep insight into a new approach for the
treatment of human tumors (16, 45). In addition, inhibi-www.aacrjournals.org
on January 14, 2015mct.aacrjournals.org Downloaded from tion of STAT3 activation is valid in inducing significant
apoptosis in both the mice model of melanoma xeno-
grafts and that of squamous cell carcinoma xenografts
(8). The induction of apoptosis in tumor is another ap-
proach to limit their uncontrolled proliferation of tumor
growth. In this process, activation of caspases is the cen-
tral event (46). Once activated, the executioner caspases
downstream of the cascade act on the key molecules in-
side the cells to orchestrate cell death. In the present
study, we observed that HO-3867 clearly induces apopto-
tic death both in vitro and in vivo, at least in part, due to
the activation of caspase-3 and cleavages of PARP. Cleav-
age of PARP by activated caspases is considered as a
marker for apoptotic death (38). STAT3 is also known
to protect cells from apoptosis through the upregulation
of Bcl-xL, Bcl-2, and survivin (15). The expression levels
in all of these molecules downstream of STAT3 activation
were clearly reduced in ovarian cancer cells by exposure
to HO-3867, not only in vitro but also in vivo—even in
mice given a low concentration (50 ppm) of HO-3867.
This implies that induction of apoptosis may be an addi-
tional contributing factor in the HO-3867–mediated inhi-
bition of ovarian tumor growth. However, further studies
are essential to elucidate the mechanism of apoptosis
induction by HO-3867.
In summary, we have investigated the anticancer effi-
cacy of a novel curcuminoid compound, HO-3867, which
inhibited ovarian tumor growth by inhibition of the
JAK1/STAT3 signaling pathway. HO-3867 shows sub-
stantial promise for further development as a potential
agent for treating ovarian cancer.Figure 6. Effect of HO-3867 on the expression of JAK/STAT3 and targeting genes. A, immunoblot analysis using tissue lysates of xenograft tumors. The
decreased expression of pSTAT3 Tyr705 and Ser727 and JAK1 are noted in the HO-3867–treated tumor lysates in a dose-dependent manner in concert with
decreased expression of both Tyr705-phosphorylated and Ser727-pSTAT3. B, the decreased expression is also shown in cyclin D1, Bcl-2, and VEGF
in a dose-dependent manner. C, cleavage of caspase-3 and PARP in HO-3867–treated tumor lysates in a dose-dependent manner. D, quantification
of cleaved caspase-3 and cleaved PARP. *, P < 0.05 versus respective untreated control group.Mol Cancer Ther; 9(5) May 2010 1177
. © 2010 American Association for Cancer Research. 
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